RecruitingNCT06462742

Microwave Ablation Versus Liver Resection for Intrahepatic Cholangiocarcinoma

Microwave Ablation Versus Liver Resection for Intrahepatic Cholangiocarcinoma Within Milan Criteria


Sponsor

Chinese PLA General Hospital

Enrollment

1,000 participants

Start Date

Jan 1, 2009

Study Type

OBSERVATIONAL

Conditions

Summary

Thermal ablation has been recommended by worldwide guidelines as first-line treatment for hepatocellular carcinoma (HCC), while evidence regarding its efficacy for primary intrahepatic cholangiocarcinoma (iCCA) is lacking. The goal of this observational study is to study the efficacy of ablation in treating iCCA by comparing its prognosis with surgery. The main questions it aims to answer are: * Whether microwave ablation could achieve similar efficacy with liver resection in treating iCCA * What is the risk factor for ablation or surgery in treating iCCA * What kind of iCCA patients could receive ablation as their first-line treatment In this real-world multicenter cohort study, we will collect data of iCCA patients from hospitals who underwent microwave ablation (MWA) or liver resection (LR) for tumors within Milan criteria. Survival will be compared between patients treated by MWA or LR.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study compares two treatments for intrahepatic cholangiocarcinoma (a type of bile duct cancer inside the liver): microwave ablation (using heat to destroy the tumor) versus liver resection surgery (removing the part of the liver with the tumor), to see which offers better outcomes for appropriate patients. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of intrahepatic cholangiocarcinoma - Your tumor meets 'Milan criteria': a single tumor ≤5 cm, or up to 3 tumors each ≤3 cm - There is no evidence of spread to major blood vessels, lymph nodes, or other organs - You are able to undergo either liver surgery or ablation with curative intent **You may NOT be eligible if...** - Your tumor exceeds the size/number limits stated above - Your cancer has spread to lymph nodes, blood vessels, or other parts of the body - You otherwise don't meet the inclusion criteria Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREMicrowave ablation (MWA) versus Liver Resection (LR)

Microwave ablation (MWA) is one of the newer modality of thermal ablation and has proven its safety and efficacy in the management of the tumors amenable for ablation for primary and metastatic diseases. Liver resection is a surgery to remove part of the liver to eradicate tumors.


Locations(1)

Chinese PLA General Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06462742


Related Trials